This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cryoglobulinaemia / Cryoglobulinemic vasculitis / Mixed cryoglobulinaemia한랭글로불린혈증 (한랭글로불린혈증성 혈관염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D89.1 (cryoglobulinemia) | ICD-9: 273.2 | Special Copayment Reduction: V294 (rare disease, reduced copayment after registration)
B. SynonymsCryoglobulinemia, Cryoglobulinemic vasculitis, Mixed cryoglobulinemia (MC), Essential mixed cryoglobulinemia (EMC), HCV-associated cryoglobulinemia
C. Adult onsetAdult onset is typical — mainly occurs in adults in their 40s to 60s and is characterized by a strong association with hepatitis C virus (HCV) infection. Higher proportion in women (F:M = 3:1). Pediatric occurrence is rare.
1. HistoryWintrobe and Buell first described cryoglobulin proteins in 1933 → Lerner and Watson named them "cryoglobulin" in 1947 → Meltzer defined the triad of mixed cryoglobulinemia in 1966 → Brouet's type I/II/III classification in 1974 → association with HCV established in 1989 → introduction of modern antiviral therapy.
2. CausesHCV infection (80–90% of types II/III), hepatitis B, HIV, EBV. Autoimmune diseases (SLE, Sjögren syndrome, RA). Lymphoproliferative disorders (multiple myeloma, Waldenström macroglobulinemia, B-cell lymphoma). Essential (15–25%, cause unknown). Cryoglobulins: immunoglobulins that precipitate reversibly at low temperature.
3. GeneticsAssociated with HLA-DR11 (DRB1*11) and HLA-DR7 susceptibility. With accompanying B-cell lymphoma, immunoglobulin heavy chain gene rearrangement (use of IgVH1-69 is characteristic). Clonal B-cell expansion. Purely hereditary cases are rare; most are acquired.
4. General epidemiologyPrevalence 1:100,000–1:1,000,000 (based on clinical manifestation). Serum cryoglobulins detected in 40–60% of HCV-infected individuals, of whom 15% develop clinical cryoglobulinemia. Relatively high occurrence in Italy and the Mediterranean region. Female predominance (about 3:1). With the declining HCV prevalence in Korea, HCV-associated cryoglobulinemia is also declining.
5. PathophysiologyHCV antigen → chronic B-cell stimulation → production of rheumatoid factor (IgM κ RF) → formation of IgM-IgG immune complexes (IC) → complement (C1q, C4) activation → IC deposition in small vessels → vasculitis. Direct infection of B cells by HCV via the CD81 receptor also promotes B-cell clonal proliferation.
6. SymptomsMeltzer triad: palpable purpura, weakness, arthralgia. Additional: Raynaud phenomenon, peripheral neuropathy (paresthesia, paralysis), renal involvement (membranoproliferative glomerulonephritis), pulmonary involvement (interstitial lung disease), skin ulcers, abdominal pain, fatigue, symptoms of liver disease.
7. SignsPalpable purpura of the lower limbs, Raynaud phenomenon, peripheral nerve deficits (sensory loss, weakness), hypocomplementemia (markedly decreased C4, normal or decreased C3), positive RF, detection of serum cryoglobulins (precipitation after cooling to 4°C), proteinuria and hematuria (renal involvement), hepatosplenomegaly (with accompanying liver disease).
8. ScreeningScreen with cryoglobulin testing when the triad of palpable purpura, Raynaud phenomenon and peripheral neuropathy occurs together. Cryoglobulin quantification (blood drawn and kept at 37°C → cooled to 4°C → precipitate fraction measured). HCV Ab + HCV RNA PCR, HBsAg, HIV, ANA, RF, C3/C4 complement, urinalysis (proteinuria, hematuria), CBC, creatinine.
9. DiagnosisDetection of serum cryoglobulins + immunoelectrophoresis (classification of immunoglobulin type, distinguishing Brouet types I/II/III). Hypocomplementemia (especially low C4). Histopathology: skin and kidney biopsy (IC deposition around small vessels, PAS-positive thrombi, membranoproliferative glomerulonephritis). Evaluation of underlying disease (HCV, B-cell lymphoma, etc.). See ACR/EULAR classification criteria, including 2 admission decision criteria.
10. TreatmentHCV-associated: direct-acting antivirals (DAA, sofosbuvir + velpatasvir, etc.) as first-line treatment; for severe vasculitis (renal, neurologic, skin necrosis), rituximab + steroids in combination; plasmapheresis for acute severe manifestations. Type I (lymphoma-associated): antilymphoma treatment. Maintenance: avoid cold exposure, nonsteroidal anti-inflammatory drugs.
11. PrognosisRemission of cryoglobulinemia in 70–80% after HCV eradication. Poor prognosis with renal involvement or transformation to B-cell lymphoma (2–10% per year). 5-year mortality about 15–20% before the HCV treatment era, greatly improved after introduction of DAA. Main causes of death: renal failure, liver cirrhosis, infection, malignancy.
12. PreventionPrevention of HCV infection (no needle sharing, prevention of sexual transmission, prevention of bloodborne infection). Prevention of cryoglobulinemia by early diagnosis of HCV and DAA treatment. Minimizing cold exposure, regular monitoring of renal function, surveillance for transformation to B-cell lymphoma.
13. ReferencesFerri C et al. Cryoglobulinemia (2004) and 9 other key papers

1. History

The history of cryoglobulinemia began with the development of serology in the 1930s. In 1933, the American hematologists Marshall Wintrobe and Bernard Buell first observed a protein in the serum of a patient with multiple myeloma that precipitated reversibly at low temperature. They reported that this protein had the reversible property of precipitating at 4°C and redissolving when rewarmed to 37°C. At the time, this discovery was regarded more as a serologic curiosity than as clinically meaningful, but it later became the cornerstone linking it to clinical disease.

In 1947, Aaron Lerner and Carl Watson analyzed sera containing cold-precipitating immunoglobulins more systematically and first introduced the term "cryoglobulin". They also recognized that cryoglobulinemia could be associated with clinical symptoms such as skin symptoms, arthralgia and circulatory disturbances. In the 1950s–60s, reports began to appear of cryoglobulinemia found in various underlying diseases (lymphoma, multiple myeloma, autoimmune diseases, infectious diseases).

In 1966, Martin Meltzer and colleagues first systematically described the classic clinical triad of cryoglobulinemia: purpura, weakness and arthralgia. They also reported that this syndrome is caused by "mixed cryoglobulin" consisting of a complex of IgM with rheumatoid factor (IgM anti-IgG antibody) activity and IgG, and named cases in which no underlying disease was found "essential mixed cryoglobulinemia (EMC)".

In 1974, Jean-Claude Brouet and colleagues published the Brouet classification (Type I, II, III) based on the immunologic composition of cryoglobulins. Type I consists of monoclonal immunoglobulin (mainly associated with lymphoproliferative disorders), type II of a mixture of monoclonal IgM (mainly RF-active IgM κ) and polyclonal IgG (most common, HCV-associated), and type III of a mixture of polyclonal IgM and polyclonal IgG (associated with autoimmune diseases). This classification is still used as the standard classification system for cryoglobulinemia.

The most important etiologic discovery was made in 1989–1990. Shortly after the discovery of hepatitis C virus (HCV) (1989, Michael Houghton, Harvey Alter, Charles Rice — awarded the 2020 Nobel Prize in Medicine), Italian researchers showed that HCV infection was the cause of most cases previously classified as "essential" mixed cryoglobulinemia. This groundbreaking discovery shifted the paradigm of cryoglobulinemia research, and chronic HCV infection was subsequently established worldwide as the most important cause of mixed cryoglobulinemia. Since 2014, with the introduction of direct-acting antivirals (DAA) making HCV cure possible, the treatment paradigm of HCV-associated cryoglobulinemia has fundamentally changed.


2. Causes

Cryoglobulinemia is a condition in which immunoglobulins that precipitate reversibly at low temperature (cryoglobulins) are present in the serum, and when these cryoglobulins deposit in small vessels and cause vasculitis, "cryoglobulinemic vasculitis" is diagnosed. The cause is approached differently according to the Brouet classification.

Causes of type I cryoglobulinemia

It is caused by monoclonal immunoglobulin and is mainly associated with lymphoproliferative disorders. Multiple myeloma (IgG or IgM monoclonal protein), Waldenström macroglobulinemia (IgM monoclonal), chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma are the main causes. In type I cryoglobulinemia, intravascular cryoglobulin precipitation occurs more extensively, and ischemic gangrene, neuropathy, retinal vascular occlusion and the like may appear.

Causes of type II and III mixed cryoglobulinemia

Hepatitis C virus (HCV) infection is the most important cause of mixed cryoglobulinemia (types II and III), with HCV infection confirmed in 80–90% of type II cryoglobulinemia. Chronic HCV infection persistently stimulates B lymphocytes, promoting production of monoclonal or polyclonal IgM with rheumatoid factor activity. Infectious causes other than HCV include hepatitis B virus (HBV), HIV, EBV (Epstein-Barr virus) and CMV (cytomegalovirus).

Among noninfectious causes, autoimmune diseases hold an important place. Sjögren syndrome is the second most common cause of mixed cryoglobulinemia, because B-cell hyperactivity is prominent in Sjögren syndrome. Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis and polymyositis are also reported as causes. Among hematologic malignancies, light chain myeloma and marginal zone B-cell lymphoma can also cause mixed cryoglobulinemia.

Essential cryoglobulinemia

When no cause is identified even after thorough exclusion of causes such as HCV, HBV, HIV, autoimmune diseases and lymphoproliferative disorders, the condition is classified as "essential mixed cryoglobulinemia". Before the introduction of DAA, more than 30% of mixed cryoglobulinemia was classified as "essential", but with advances in HCV testing technology (HCV RNA PCR testing), the actual proportion of essential cases has fallen to about 10–15%. Because this group is at risk of later developing B-cell lymphoma, long-term follow-up is needed.


3. Genetics

Cryoglobulinemia is not a purely hereditary disease but an acquired immune abnormality that mostly arises later in life. However, certain genetic backgrounds are known to increase susceptibility to developing cryoglobulinemia.

HLA gene associations

In HCV-associated mixed cryoglobulinemia, the HLA-DR11 (DRB1*11) allele is reported to increase susceptibility, and this association is clear in Italian and Mediterranean populations. HLA-DR7 is also reported as a susceptibility allele in some studies. HLA genotype affects the processing and presentation of HCV antigens and the efficiency of B-cell stimulation, and is one factor explaining interindividual differences in cryoglobulin production.

Characteristics of B-cell gene rearrangement

In mixed cryoglobulinemia, the B-cell clones producing cryoglobulins show a characteristic pattern of immunoglobulin heavy chain variable region (IgVH) gene usage. In HCV-associated type II cryoglobulinemia, B cells producing IgM κ with rheumatoid factor activity characteristically use IgVH1-69 (formerly V1-69 or 51p1), at a frequency markedly higher than VH gene usage in normal B cells. This specific IgVH usage reflects clonal antigen-driven expansion of B cells against specific HCV structural proteins. This clonal B-cell expansion is the molecular basis of the risk of transformation from cryoglobulinemia to B-cell lymphoma (especially marginal zone B-cell lymphoma).

Other genetic predispositions

Variants in complement regulatory genes (C4 deficiency, C1q receptor polymorphisms) can impair the efficiency of immune complex clearance and affect the severity of cryoglobulinemic vasculitis. In addition, Fc receptor (FcγR) polymorphisms can affect phagocytic clearance of immune complexes and contribute to vascular deposition and the degree of vasculitis. These genetic polymorphisms partly explain why only some patients with the same HCV infection develop clinical cryoglobulinemia.


4. General epidemiology

The prevalence and incidence of cryoglobulinemia differ greatly depending on whether criteria are based on clinical manifestation or serologic detection. Using serum cryoglobulin positivity alone, prevalence is much higher, but the prevalence of clinical cryoglobulinemia (with symptoms of vasculitis) is estimated at 1–25 per 100,000 population.

HCV-associated epidemiology

Serum cryoglobulins are detected in 40–60% of people with chronic HCV infection, but clinical symptoms appear in only about 15% or fewer of them. Considering the number of HCV-infected people worldwide (about 58 million, WHO 2019 estimate), the number of patients with HCV-associated cryoglobulinemia is estimated to reach several million. High prevalence is reported in Mediterranean and Middle Eastern regions with high HCV prevalence, such as Italy, Spain and Egypt. In Korea, the number of HCV-infected people is estimated at about 200,000–300,000 (as of the 2020s), and with the expansion of DAA treatment, the prevalence of HCV-associated cryoglobulinemia is expected to continue to decline.

Sex and age

In mixed cryoglobulinemia, the proportion of women is significantly higher (F:M about 3:1), similar to the sex distribution of autoimmune diseases in general. The age of onset is mainly the 40s to 60s. Type I cryoglobulinemia follows the age of onset of the underlying lymphoproliferative disorder and is more common at older ages (60s–70s).

Epidemiologic features in Korea

In Korea, large-scale epidemiological data on cryoglobulinemia are limited, but analysis of National Health Insurance claims data confirms that the number of patients registered under code D89.1 is very small, meeting the rare disease criteria. In Korean HCV patients who develop cryoglobulinemia, HCV cure with DAA treatment (sofosbuvir + velpatasvir or glecaprevir + pibrentasvir, etc.) is the priority approach, and with the expanded use of this treatment in Korea, the frequency of cryoglobulinemia is expected to decrease.


5. Pathophysiology

The pathophysiology of cryoglobulinemic vasculitis is broadly divided into ① the mechanism of cryoglobulin production and ② the mechanism of vascular damage by cryoglobulins.

Chronic B-cell stimulation by HCV and cryoglobulin production

HCV binds through its E2 envelope protein to CD81 (a tetraspanin receptor) on the B-cell surface and directly stimulates B cells. CD81 is a component of the CD19/CD21 B-cell receptor complex, and E2–CD81 binding by HCV lowers the threshold for B-cell activation, promoting B-cell proliferation even without antigen-specific stimulation. Persistent HCV antigen stimulation (mainly HCV core protein and E2 protein) acts together with nonspecific stimulation through CD81, selectively expanding B-cell clones that produce IgM κ (mainly monoclonal or oligoclonal) with rheumatoid factor (RF) activity. This IgM RF binds polyclonal IgG (including HCV-specific antibodies) to form IgM-IgG immune complexes, and these complexes make up the cryoglobulin (with the property of precipitating at low temperature).

Vascular damage by immune complexes

The IgM-IgG immune complexes formed (cryoglobulins) tend to precipitate in peripheral small vessels (capillaries, venules, arterioles) exposed to temperatures below body temperature. The precipitated immune complexes activate the classic complement pathway, consuming C1q, C4, C2 and C3. As a result, the serum C4 concentration is markedly decreased (C3 is often normal or mildly decreased), and vascular endothelial cell damage occurs through formation of the membrane attack complex (MAC). Activated complement fragments (C3a, C5a) activate neutrophils and mast cells, amplifying the inflammatory response. Immune complexes and complement deposited in the vessel wall cause increased vascular permeability, vascular occlusion and vessel wall necrosis, producing clinical manifestations such as skin purpura, glomerulonephritis and peripheral neuropathy.

Mechanism of renal involvement (cryoglobulinemic membranoproliferative glomerulonephritis)

In the kidney, cryoglobulin immune complexes deposit in the glomerular capillary walls, causing membranoproliferative glomerulonephritis (MPGN). Characteristic findings are double contour formation of the glomerular basement membrane on light microscopy, granular deposits of IgM, IgG and C3 on immunofluorescence, and reticular tubular inclusions (intraluminal thrombi, PAS-positive) on electron microscopy. Renal involvement occurs in 20–30% of patients with cryoglobulinemia and can progress to renal failure.

Mechanism of peripheral neuropathy

Cryoglobulin deposition in peripheral nerves and occlusion of epineural vessels by vasculitis cause ischemic nerve damage. In addition, cryoglobulins themselves may have autoantibody properties that cross-react with peripheral nerve components (myelin-associated glycoprotein, etc.), also contributing to direct nerve damage.


6. Symptoms

The clinical symptoms of cryoglobulinemia vary depending on the organs involved and the cryoglobulin type. Symptoms of involvement of several organs, including the classic Meltzer triad, may appear in combination.

Classic Meltzer triad

Palpable purpura is the most characteristic skin symptom of cryoglobulinemia, appearing as non-blanching, palpable maculopapules 1–4 mm in size concentrated on the lower limbs (especially the calves and ankles). It tends to worsen with cold exposure or prolonged standing. Weakness presents as general fatigue and systemic lassitude and corresponds to an overall loss of energy rather than muscle weakness. Arthralgia is a nondeforming, migratory joint pain mainly involving large joints such as the knees, ankles and wrists; advanced joint destruction is rare.

Renal symptoms

Renal involvement occurs in 20–30% of all cryoglobulinemia, with a wide spectrum from asymptomatic proteinuria and hematuria to nephrotic syndrome and renal failure. Hematuria (microscopic or gross), foamy urine (with proteinuria), edema (with hypoalbuminemia) and hypertension may appear. When it presents as rapidly progressive glomerulonephritis (RPGN), it can progress to acute renal failure within weeks, so early recognition and treatment are essential.

Symptoms of peripheral neuropathy

Peripheral nervous system involvement occurs in 50–70% of cryoglobulinemia, commonly with sensory abnormalities (numbness, burning, stabbing sensations) beginning in the distal lower limbs and, with progression, muscle weakness (foot drop, gait disturbance). Sensory peripheral neuropathy is the most common, and when motor nerve involvement accompanies it, limitation of daily functioning occurs. A mononeuritis multiplex pattern may also appear.

Symptoms in other organs

Raynaud phenomenon appears on cold exposure as a three-color change of pallor, cyanosis and flushing of the fingers and toes; it is more common in type I cryoglobulinemia and in severe cases can progress to ischemic gangrene. Hepatic symptoms may include chronic fatigue, right upper quadrant pain and jaundice (with progression) related to underlying HCV hepatitis. Pulmonary involvement is rare, but dyspnea may appear due to interstitial lung disease or pulmonary vascular involvement. In some patients, abdominal pain (mesenteric vascular involvement) and visual abnormalities (retinal vascular involvement) are also reported.


7. Signs

On physical examination and laboratory findings, the following signs characteristic of cryoglobulinemia are observed.

Skin signs

Palpable purpura of the lower limbs is the most characteristic skin sign. Pathologically, it shows findings of leukocytoclastic vasculitis. In severe cases, skin ulceration and areas of necrosis may develop. Pallor and cyanotic discoloration due to Raynaud phenomenon and digital ischemia are also observed. Skin purpura worsens after cold exposure or prolonged standing and may partly improve with leg elevation or keeping warm.

Laboratory findings

Detection of serum cryoglobulins is the key to diagnosis. Proper specimen handling (keeping the sample at 37°C immediately after collection, separating the serum, and checking for precipitation after cooling at 4°C for 72 hours or more) is essential. Hypocomplementemia is a characteristic laboratory finding of mixed cryoglobulinemia, with a markedly decreased C4 concentration (sometimes at undetectable levels) while C3 is normal or mildly decreased. This pattern of selective C4 decrease reflects classic pathway complement activation and helps differentiate it from SLE (both C3 and C4 decreased). Positive rheumatoid factor (RF): in mixed cryoglobulinemia, RF (IgM anti-IgG) is positive at a high titer. A monoclonal protein band (types I, II) may be observed on serum protein electrophoresis and immunoelectrophoresis.

Renal findings

Urinalysis may show proteinuria (24-hour urine protein >0.5 g), hematuria (including red blood cell casts) and tubular casts. Elevated serum creatinine is an indicator of renal failure.

Neurologic findings

Nerve conduction studies (NCS)/electromyography (EMG) confirm a distal-predominant sensorimotor polyneuropathy pattern or a mononeuritis multiplex pattern. Skin biopsy (evaluation of small fiber neuropathy) is used to evaluate sensory abnormalities.


8. Screening

Systematic screening for cryoglobulinemia begins with recognition of the characteristic clinical syndrome (the triad of purpura, weakness and arthralgia). In addition, screening tests are considered in patients with HCV infection, autoimmune diseases or lymphoproliferative disorders.

Step 1: clinical recognition and basic tests

Screening for cryoglobulinemia is performed in the following clinical situations: ① palpable purpura of unknown cause, ② Raynaud phenomenon + purpura worsening after cold exposure, ③ peripheral neuropathy of unknown cause + purpura, ④ vasculitis symptoms in patients with HCV infection, ⑤ membranoproliferative glomerulonephritis of unknown cause. Basic screening tests include CBC (checking for anemia, thrombocytopenia), serum creatinine, urinalysis (proteinuria, hematuria), ESR/CRP, LFT (liver function), RF and ANA.

Step 2: cryoglobulin-specific tests

For the cryoglobulin detection test, the specimen handling method is important. Immediately after blood collection, the serum is separated in a 37°C incubator and then stored in a 4°C refrigerator for at least 72 hours (ideally 7 days) to check for precipitate formation. If a precipitate is found, it is rewarmed to 37°C to check whether it redissolves (reversibility), and the precipitate fraction (cryocrit) and protein concentration are measured. Immunoelectrophoresis or immunofixation electrophoresis of the precipitated protein determines the Brouet classification (types I/II/III). If a monoclonal component (IgM κ, etc.) is identified, a lymphoproliferative disorder is evaluated in consultation with hematology-oncology.

Step 3: tests for underlying disease

HCV: anti-HCV antibody + quantitative HCV RNA PCR (confirmation of HCV infection and assessment of viral load). HBV: HBsAg, HBeAg, HBV DNA. HIV: HIV Ab/Ag test. Autoimmune diseases: ANA, anti-dsDNA, anti-Sm (SLE), anti-SSA/SSB (Sjögren), RF, ACPA. Lymphoproliferative disorders: serum protein electrophoresis, immunofixation electrophoresis, serum free light chains (FLC), bone marrow biopsy (if needed), PET-CT or CT (assessment of lymph node and spleen enlargement). Serum C3 and C4 complement measurement (confirmation of hypocomplementemia). LDH (indicator of cell damage and lymphoma activity).


9. Diagnosis

Detection of serum cryoglobulins is essential for diagnosing cryoglobulinemia, and integrated judgment of clinical symptoms and serologic findings is required. In 2011, ACR/EULAR published classification criteria for cryoglobulinemic vasculitis.

Overview of diagnostic criteria

The classification criteria for cryoglobulinemic vasculitis (Vasculitis Clinical Research Consortium, 2011) include ① palpable purpura or skin ulcers, ② positive serum cryoglobulins, ③ hypocomplementemia (decreased C4), ④ renal involvement (proteinuria or hematuria), ⑤ peripheral neuropathy and ⑥ leukocytoclastic vasculitis on skin biopsy. If 3 or more of these are met, the condition can be classified as cryoglobulinemic vasculitis.

Brouet classification (immunoelectrophoresis)

Analysis of cryoglobulin composition is essential for deciding the direction of treatment. Type I: only monoclonal immunoglobulin detected (IgG or IgM monoclonal), associated with lymphoproliferative disorders. Type II: mixture of monoclonal IgM (mainly κ light chain, RF-active) + polyclonal IgG, most commonly HCV-associated. Type III: mixture of polyclonal IgM + polyclonal IgG, associated with autoimmune diseases (Sjögren, SLE). Types II and III together are called "mixed cryoglobulinemia (MC)".

Histopathology

Skin biopsy: characterized by leukocytoclastic vasculitis of small dermal vessels at purpuric sites, PAS-positive intravascular thrombi (= cryoglobulin precipitates) and positive immunofluorescence for IgM, IgG and C3 in vessel walls. Kidney biopsy: characterized by a membranoproliferative glomerulonephritis (MPGN) pattern, double contours of the glomerular basement membrane, hyaline intraluminal thrombi (= cryoglobulin precipitates), granular deposits of IgM, IgG and C3 on immunofluorescence, and subendothelial deposits with a microcrystalline or fingerprint appearance (crystalloid deposits) on electron microscopy.

Differential diagnosis

Differentiation is needed from IgA vasculitis (Henoch-Schönlein purpura, positive IgA immunofluorescence), hypersensitivity vasculitis (drug-induced), SLE vasculitis (both C3 and C4 decreased, positive dsDNA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (positive MPO-ANCA or PR3-ANCA) and thrombotic thrombocytopenic purpura (TTP, decreased ADAMTS13).


10. Treatment

Treatment of cryoglobulinemia aims at treating the underlying cause and controlling the vasculitis itself, and a tailored approach according to Brouet type and clinical severity is needed.

HCV-associated cryoglobulinemia: direct-acting antivirals (DAA)

In HCV-associated type II/III cryoglobulinemia, HCV cure (sustained virological response, SVR) is the most important treatment goal. With DAA-based HCV treatment (12–24 weeks, pangenotypic regimens of sofosbuvir + velpatasvir or glecaprevir + pibrentasvir), an SVR of 95% or more can be achieved, and after SVR is achieved, clinical remission of cryoglobulinemia occurs in 70–80% of patients. Normalization of cryoglobulin levels and complement recovery may take several months to more than 1 year after SVR, so follow-up monitoring is needed. In severe renal involvement or severe vasculitis, immunosuppressive treatment is given together with DAA treatment.

B-cell–targeted treatment with rituximab

Rituximab (anti-CD20 monoclonal antibody, 375 mg/m² IV once weekly × 4 or 1,000 mg × 2) is the immunomodulatory treatment with the highest level of evidence, directly targeting the B-cell clones that produce cryoglobulins. Rituximab is recommended first particularly in ① vasculitis persisting despite HCV DAA treatment, ② renal involvement (proteinuria >1 g/day, reduced renal function), ③ severe peripheral neuropathy and ④ skin ulcers and extensive purpura. Assessment of the risk of HBV reactivation by HBsAg and HBcAb testing is essential before rituximab administration. If there is active HCV infection, it must be combined with HCV treatment.

Corticosteroids and immunosuppressants

For acute severe vasculitis (RPGN, severe nerve involvement, extensive skin ulcers), high-dose steroids (methylprednisolone 0.5–1 g/day IV as 3-day pulse therapy, followed by maintenance with oral prednisolone 1 mg/kg/day) are used short-term. Combination with rituximab is recommended. Cyclophosphamide may be used instead of or in combination with rituximab in severe renal or nerve involvement. Long-term steroid monotherapy can promote HCV viral replication, so caution is needed.

Plasmapheresis

In acute severe presentations, especially rapidly progressive glomerulonephritis, severe nerve involvement, or skin ischemia and gangrene, plasmapheresis is performed to rapidly remove circulating cryoglobulins from the blood. Therapeutic plasma exchange is generally performed 3–5 times, every other day or 3 times a week, in combination with rituximab or steroids. Immunosuppressive treatment is given concurrently in preparation for a rebound increase in anti-cryoglobulin antibodies (IgM) after plasmapheresis.

Treatment of type I cryoglobulinemia

Antitumor treatment of the underlying lymphoproliferative disorder (multiple myeloma, Waldenström macroglobulinemia, B-cell lymphoma) is most important. Bortezomib-based regimens are used in multiple myeloma, and rituximab + bendamustine or ibrutinib in Waldenström macroglobulinemia.

Nonpharmacologic management

Avoiding cold exposure: because cryoglobulin precipitation is promoted at low temperatures, adequate warmth in winter and in cold environments is important for preventing symptom worsening. Warming intravenous fluids: during inpatient treatment, intravenous fluids are warmed to 37°C to prevent intravascular cryoglobulin precipitation.


11. Prognosis

The prognosis of cryoglobulinemia differs greatly depending on the underlying cause, the extent of organ involvement and the response to treatment. It needs to be understood separately for the treatment era before the introduction of DAA and the era after.

Changes in prognosis in the HCV DAA treatment era

Since 2014, the introduction of highly effective DAA treatment for HCV (SVR of 95% or more) has dramatically improved the prognosis of HCV-associated cryoglobulinemia. After SVR is achieved, complete remission or marked improvement of vasculitis occurs in 70–80% of patients. Reduction of proteinuria, disappearance of hematuria and improvement of peripheral nerve symptoms appear over several months, and in some patients cryoglobulin levels normalize completely. However, when severe kidney damage (severely reduced GFR) or irreversible nerve damage has occurred, complete functional recovery may be difficult even after SVR, which underscores the importance of early diagnosis.

Renal prognosis

The prognosis is poor when there is renal involvement. Combined rituximab + DAA treatment stabilizes or improves renal function, but delayed treatment can lead to chronic renal failure. In cryoglobulinemic MPGN, residual proteinuria commonly remains even after treatment.

Risk of transformation to B-cell lymphoma

In mixed cryoglobulinemia, transformation to B-cell non-Hodgkin lymphoma (mainly marginal zone lymphoma) is reported at a risk of 2–10% per year. This risk is higher when HCV infection persists, and eliminating HCV with DAA treatment reduces the risk of lymphoma transformation. Therefore, regular assessment of lymph nodes and spleen and follow-up serum protein electrophoresis are needed in patients with cryoglobulinemia.

Mortality

Before DAA treatment, the 5-year mortality of HCV-associated cryoglobulinemia was about 15–20%, and the main causes of death were liver cirrhosis and hepatocellular carcinoma (direct complications of HCV), renal failure, infection and B-cell lymphoma. Since the introduction of DAA, these risks of death have decreased greatly, but a poor prognosis is still observed in patients with delayed diagnosis or severe organ damage.


12. Prevention

Prevention of cryoglobulinemia focuses mainly on preventing or treating early the underlying disease (especially HCV infection).

Primary prevention: preventing HCV infection

The most effective primary prevention of HCV-associated cryoglobulinemia is blocking HCV infection itself. Specifically, this includes use of disposable syringes by people who inject drugs (no needle sharing), compliance with appropriate infection prevention guidelines in medical institutions (preventing blood exposure), HCV screening of blood for transfusion (performed by Korean blood centers) and education on awareness of the risk of sexual transmission. A vaccine against HCV is currently in clinical development, and no preventive vaccine is yet available.

Secondary prevention: early diagnosis and treatment of HCV

Starting DAA treatment early in all patients with confirmed HCV infection is the most important secondary prevention strategy for preventing cryoglobulinemia. Because cryoglobulin production and B-cell clonal expansion may be progressing even in people with asymptomatic HCV infection, prompt initiation of treatment is recommended at HCV diagnosis. Regular HCV screening in high-risk groups (people who inject drugs, family members of HCV patients, hemodialysis patients, etc.) is also an important means of secondary prevention.

Prevention of complications (tertiary prevention)

To prevent complications in patients already diagnosed with cryoglobulinemia, measures include ① preventing symptom worsening by minimizing cold exposure (adequate warmth in winter, care with contact with cold water), ② early detection of renal involvement by regular renal function monitoring (urinalysis, serum creatinine), ③ assessment of disease activity and surveillance for transformation to B-cell lymphoma through regular serologic follow-up (serum protein electrophoresis, cryoglobulin levels, C4 complement), ④ prevention of osteoporosis and glucose abnormalities with long-term steroid use, and ⑤ monitoring for hepatitis B reactivation before and after rituximab administration.


13. References

  1. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55(1):4–13. DOI: 10.1136/jcp.55.1.4. PMID: 11825916.

  2. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775–788. DOI: 10.1016/0002-9343(74)90852-3. PMID: 4216269.

  3. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348–360. DOI: 10.1016/S0140-6736(11)60242-0. PMID: 22075453.

  4. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128(9):950–955. DOI: 10.1016/j.amjmed.2015.02.017. PMID: 25837823.

  5. Saadoun D, Resche Rigon M, Pol S, et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinaemia vasculitis. Ann Rheum Dis. 2015;74(5):834–840. DOI: 10.1136/annrheumdis-2013-204653. PMID: 24406542.

  6. Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473–1482. DOI: 10.1002/hep.28753. PMID: 27481488.

  7. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843–853. DOI: 10.1002/art.33412. PMID: 21953143.

  8. Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119(25):5996–6004. DOI: 10.1182/blood-2011-12-396028. PMID: 22566604.

  9. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia — a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. 1966;40(6):837–856. DOI: 10.1016/0002-9343(66)90199-0. PMID: 5327222.

  10. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39(1):2–17. DOI: 10.1016/j.dld.2006.06.008. PMID: 16978930.